Open AccessFeasibility of CYFRA 21‐1 as a serum biomarker for the detection of colorectal adenoma and advanced colorectal adenoma in people over the age of 45
Author(s) -
Lim Do Hyoung,
Lee Jai Hyuen,
Kim Jong Wan
Publication year - 2018
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22163
Subject(s) - medicine , gastroenterology , adenoma , cytokeratin , asymptomatic , colorectal cancer , colorectal adenoma , biomarker , tumor marker , confidence interval , immunoassay , colorectal polyp , receiver operating characteristic , pathology , immunohistochemistry , cancer , antibody , colonoscopy , immunology , biochemistry , chemistry
Background Colon adenoma ( CA ) is a premalignant lesion of colorectal cancer, and its early removal is closely associated with more prolonged survival in the general population. In this study, we aimed to evaluate the relationship between diverse biologic markers and a newly diagnosed CA and to predict the clinical possibility of cytokeratin‐19 soluble in serum fragment ( CYFRA 21‐1) as a screening tool in asymptomatic adults aged over 45 years. Methods Four hundred and seventy‐nine patients with a histologically confirmed CA or benign colon polyp ( BCP ), 76 patients with only benign colorectal diseases and 223 negative controls with no CA or BCP detected on colonofibroscopy were investigated. Multiple tumor markers and biochemical markers were simultaneously checked by radioimmunoassay and enzyme immunoassay. Results The CYFRA 21‐1 alone showed significant stepwise contrastive potential among the three groups ( P <.001). Based on the receiver operating characteristic ( ROC ) analysis, Area under the curve ( AUC ) for CYFRA 21‐1, with a value of 0.732 (95% confidence interval, 0.656‐0.809, P <.001) for differentiating between negative controls and patients with advanced colon adenoma, was comparatively the highest among all analyzed factors. The sensitivity of CYFRA 21‐1 was significantly higher than that of the other tumor markers in the diagnosis of CA and advanced CA , respectively ( P <.001). Conclusions Considering the results of our study, CYFRA 21‐1 showed a significant diagnostic performance and significant stepwise comparative potential in differentiating patients with CA from benign controls. CYFRA 21‐1 could be a simple and effective screening test for the diagnosis of CA .